Hepatitis
Hepatitis 05/01/2012
Roche's novel tests for the management of hepatitis C virus infection receive CE mark
Tests change hepatitis C disease and patient management.
Hepatitis 05/01/2012
ACH-1625 receives Fast Track designation from the FDA for the treatment of chronic hepatitis C
ACH-1625 is a once-daily protease inhibitor with broad genotypic coverage against HCV that was discovered by Achillion and is currently being evaluated in a Phase 2 clinical trial.
Hepatitis 05/01/2012
Experimental hepatitis C vaccine shows early promise
A new vaccine against the chronic liver disease hepatitis C has shown promising results in an early-stage clinical trial in humans, British and Italian scientists said Wednesday.
Hepatitis 02/01/2012
Hepatitis C virus hijacks liver microRNA
Mechanism explains how virus survives in the liver and how a new antiviral works.
Hepatitis 30/12/2011
Peregrine provides update on HCV clinical program
Preliminary data from Phase II study shows antiviral activity and positive safety profile at both bavituximab doses evaluated; Supporting further dosing and combination studies; Company to seek collaboration to advance HCV program while continuing to focus on its lead bavituximab clinical program in multiple solid tumor indications including lung cancer.
Hepatitis 30/12/2011
Early guidance on use of hepatitis C protease inhibitors in HIV-co-infected patients
“HIV/hepatitis C virus-co-infected persons should be included at earlier stages in drug development so that practical guidance can be based more on data and less on expert opinion.”
Hepatitis 23/12/2011
FDA: Intron A (Interferon alfa-2b) product labeling changes
Reflecting more accurately recommendations for initiating and monitoring alpha interferon treatment in patients with histories of psychiatric and substance use disorders.
Hepatitis 23/12/2011
FDA: Important updates to PegIntron labeling
Approved revisions to the product labeling for PegIntron include the use of PegIntron with hepatitis C virus NS3/4A protease inhibitors for the treatment of genotype 1, chronic hepatitis C infection.
Hepatitis 23/12/2011
FDA: Tyzeka (telbivudine) labeling updates re: use with pegylated interferon alfa-2a
Approved revisions to the product labeling for Tyzeka (telbivudine) include a contraindication regarding the use of Tyzeka with Pegasys (pegylated interferon alfa-2a) due to increase risk and severity of peripheral neuropathy.
Hepatitis 16/12/2011
Pharmasset announces intent to amend QUANTUM trial
The company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938.
Hepatitis 16/12/2011
Merck announces initiation of clinical development collaboration with Roche to evaluate investigational combination regimens for the treatment of chronic hepatitis C genotype 1 infection
New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir).
Hepatitis 13/12/2011
Co-infection with hepatitis B worsens HIV-related outcomes
Co-infection with hepatitis B virus increases the risk of AIDS or death for patients newly diagnosed with HIV.
Hepatitis 13/12/2011
Hepatitis B genotype B associated with poorer liver-related outcomes in Taiwanese patients co-infected with HIV and hepatitis B
Patients with genotype B co-infection are more likely to experience acute exacerbations of hepatitis, HBeAg seroconversion, lamivudine resistance, and liver disease-related death than those with genotype C coinfection when they receive HIV therapy containing lamivudine as the only active agent against hepatitis B virus.
Hepatitis 12/12/2011
The hepatitis C market: Biotech’s version of the Daytona 500
The medical advances in hepatitis C have been dizzying this year, especially in what it means in terms of multi-billion dollar business implications.
Hepatitis 10/12/2011
Vertex and Alios BioPharma begin clinical studies of nucleotide drug candidates ALS-2200 and ALS-2158 for the treatment of hepatitis C
Studies to evaluate safety and effects on viral kinetics in people with chronic genotype-1 hepatitis C; Data expected in second quarter of 2012 could enable initiation of interferon-free, nucleotide-based combination studies in the second half of 2012.
Hepatitis 10/12/2011
Boehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis C
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335 - an investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus.
Hepatitis 09/12/2011
HCV infection may predict coronary artery disease
Coronary artery disease is significantly more prevalent in patients with hepatitis C virus infection.
Hepatitis 09/12/2011
Green tea compound may prevent post-transplant hep C recurrence
An antioxidant component of green tea blocks the ability of the hepatitis C virus (HCV) to enter liver cells (hepatocytes), making it potentially useful in protecting the liver against infection with the virus, notably following transplant surgery when there is a high risk of disease recurrence.
Hepatitis 09/12/2011
Hepatitis C doesn't affect cognitive function of women, but some evidence HIV does
Infection with hepatitis C does not affect the cognitive performance of women with or at risk of HIV but the investigators do not regard their findings as definitive.
Hepatitis 07/12/2011
Biotron announces positive three month data for BIT225 - 87% virus free
87% of HCV trial patients receiving BIT225 have undetectable virus at the three month time point.
More...
